Loading...
Bilateral Trade Intelligence · $34.5M Total Trade · 145 Exporters · 142 Buyers · DGFT Verified · Updated March 2026
India exported $34.5M worth of pharmaceutical formulations to Yemen across 2,863 verified shipments, sourced from 145 Indian exporters supplying 142 Yemen buyers. The top exporters are CIPLA LIMITED ($4.0M) and MEDICEF PHARMA ($2.2M). The leading products are Vaccine ($1.4M) and Paracetamol ($461K). Average shipment value: $12.0K.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Other Mix Vaccine-liquid Vaccine | $1.4M | 4.0% |
| 2 | Zinnia F 3x28 S Yemen Moh Packs 530208 | $1.3M | 3.9% |
| 3 | Solpafizz (paracetamol 500 MG + Caffeine 65 MG Effervescent Tablets) | $461.1K | 1.3% |
| 4 | Ph.dru.& Med.: Human Albumin EP 20% Solution (albucel (ep) 10g/50ml) [1x50ml] | $380.6K | 1.1% |
| 5 | Erythromycin Stearate Tablets BP 250mg (47388 X 10 X 10 ) -box | $317.5K | 0.9% |
| 6 | Rifampin & Isoniazid Tablets 24x28t Rifampin 150mg and Isoniazid 75mg Tablets | $307.0K | 0.9% |
| 7 | Rifa150+inh75+pzn400+etb275 24x28t Gdf Rifampicin, Isoniazid, Pyrazinamide and… | $288.9K | 0.8% |
| 8 | Ceficad 1000 (r/m : Cefepime for Injection U) Batch Ei063e5001 to Ei063e5009 Mf… | $271.1K | 0.8% |
| 9 | Ceftriaxone for Injection (each Vial Contains:ceftriaxone Sodium (sterile) USP… | $260.7K | 0.8% |
| 10 | Pharmaceutical Medicines Ace Miso Tablets Batch No. Ace2501001 to Ace2501019 | $236.2K | 0.7% |
| 11 | Dispersible Paracetamol Tablets BP 250mg(120000 X 10 X 10) - Box | $214.8K | 0.6% |
| 12 | Enclex-40 Injection ( Inv. Qty. 16500 Pack 2 X 0.4 ML = 33 | $210.7K | 0.6% |
| 13 | Ciplacef 1000 Injection 1gm 1 X 1 Gm + Wfi | $198.1K | 0.6% |
| 14 | Lev Protec Nor 0.03mg 1x28 Ye Packs 383680 | $197.8K | 0.6% |
| 15 | Oritaxim 1000 with Wfi (r/m : Combipack of Cefotaxime 1000mg USP & Sterile Wate… | $174.3K | 0.5% |
India exports 20+ pharmaceutical formulations to Yemen with a combined trade value of $34.5M. Key products include Vaccine ($1.4M), Paracetamol ($461K), Erythromycin ($317K), Isoniazid ($307K), Ceftriaxone ($261K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 2,863 verified Indian Customs (DGFT) shipment records.
Historical evolution, India's market position, and recent developments
The pharmaceutical trade between India and Yemen has experienced significant growth over the past decade. In 2019, India's pharmaceutical exports to Yemen were valued at approximately $29.28 million. By 2024, this figure had increased to $80.48 million, indicating a robust expansion in bilateral trade. This upward trajectory reflects India's growing role as a key supplier of pharmaceutical products to Yemen, driven by the increasing demand for quality medicines in the region.
India holds a dominant position in Yemen's pharmaceutical import market. In 2022, India was the leading exporter of "Other medicaments of mixed or unmixed products" to Yemen, with exports valued at $37.24 million. This substantial share underscores India's strategic importance in meeting Yemen's pharmaceutical needs, particularly in providing a diverse range of medications.
Between 2024 and 2026, several key developments have influenced the India-Yemen pharmaceutical trade. In September 2025, Amber Lifesciences initiated pharmaceutical contract manufacturing services in South Yemen, aiming to support healthcare needs in regions with limited local manufacturing capacity. Additionally, in February 2026, the United Nations COMTRADE database updated India's pharmaceutical exports to Yemen, reflecting ongoing trade activities and the dynamic nature of the market.
These are the top pharmaceutical products exported from India to Yemen, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Yemen buyers, regulatory requirements, and logistics for that specific product corridor. Products include Vaccine ($1.4M), Paracetamol ($461K), Erythromycin ($317K), Isoniazid ($307K), Ceftriaxone ($261K) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
145 Indian pharmaceutical companies export finished formulations to Yemen. Leading exporters include Cipla Limited, Medicef Pharma, Scott Edil Pharmacia Limited, Serum Institute Of India Private Limited. The top exporter accounts for 11.7% of total India–Yemen pharma exports. Source: Indian Customs (DGFT).
142 companies in Yemen import pharmaceutical formulations from India. Top buyers include Medica Pharmaceutical Industries L, Al Jabal Drugs & Medical Appliance, Unfpa Yemen, Xxrumxxifexxciexxes Xxd. The largest buyer accounts for 6.5% of India–Yemen pharma imports. Source: Indian Customs (DGFT).
EXPORT_REGULATORY
Registration process, GMP requirements, import documentation
Indian pharmaceutical companies seeking to register products in Yemen must adhere to the guidelines set by the Supreme Board of Drugs and Medical Appliances (SBDMA). The registration process requires a comprehensive product dossier, including administrative documents such as a Free Sales Certificate (COPP) legalized by the Yemeni embassy, and pharmaceutical documents detailing the product's composition, manufacturing process, and stability studies. Additionally, a Site Master File is required, and an agent's distribution agreement must be legalized by the Yemeni embassy. Notably, a Good Manufacturing Practice (GMP) inspection is mandatory if the company is not registered in the Gulf Cooperation Council (GCC) countries.
Yemen mandates that pharmaceutical products imported into the country comply with international GMP standards, such as those recognized by the World Health Organization (WHO). Manufacturing facilities must undergo inspections to verify adherence to these standards. The inspection process includes evaluating the facility's quality control, hygiene, and sanitation protocols. Mutual recognition agreements may expedite the approval process for manufacturers already certified by recognized authorities.
To import pharmaceutical products into Yemen, companies must provide several key documents:
Additionally, import licenses and compliance with customs procedures are required for pharmaceutical imports into Yemen.
EXPORT_TRENDS
Dominant categories, emerging opportunities, and demand drivers
India's pharmaceutical exports to Yemen are predominantly in the category of "Other medicaments of mixed or unmixed products." In 2022, India exported $37.24 million worth of these products to Yemen, making it the largest exporter in this category. This dominance aligns with Yemen's healthcare needs, which include a diverse range of medications to address various health conditions.
The global pharmaceutical industry is witnessing patent expirations, leading to increased demand for generic medicines. India, being a major producer of generics, is well-positioned to meet this demand in Yemen. Additionally, the rising prevalence of chronic diseases in Yemen presents opportunities for Indian exporters to supply specialized medications and biosimilars.
Yemen's disease burden, including high rates of infectious diseases and chronic conditions, drives the demand for pharmaceutical imports. The aging population and limited local manufacturing capacity further contribute to the reliance on imported medicines. Healthcare spending trends indicate a growing allocation of resources towards pharmaceuticals, enhancing the market potential for Indian exporters.
EXPORT_POLICY
Tariff structure, trade agreements, IP and patent landscape
Yemen's tariff structure for pharmaceutical imports includes Most Favored Nation (MFN) tariff rates and preferential rates for certain countries. Duty exemptions may apply to specific pharmaceutical formulations, particularly those addressing critical health needs. However, detailed and up-to-date information on these rates is not readily available and may require direct consultation with Yemeni customs authorities.
Yemen is a member of the Arab Free Trade Area (AFTA), which aims to reduce trade barriers among member countries. While there is no specific Free Trade Agreement (FTA) between India and Yemen, the AFTA framework may facilitate trade between the two nations. Current or upcoming negotiations could further enhance bilateral trade relations.
Yemen's intellectual property (IP) laws, including patent provisions and data exclusivity, are evolving. Compulsory licensing may be granted in cases of public health emergencies, potentially affecting the entry of Indian generics into the Yemeni market. Indian exporters should monitor these developments to navigate the IP landscape effectively.
EXPORT_LOGISTICS
Shipping routes, port infrastructure, cold chain compliance
Major sea routes from Indian ports to Yemen include the Arabian Sea and the Gulf of Aden. Transit times vary depending on the specific ports of departure and arrival. Air routes are also utilized, with transit times depending on the specific airports involved. Geopolitical factors, such as the security situation in the Red Sea, can impact shipping routes and schedules.
In India, key export ports include Nhava Sheva Sea (INNSA1), Mundra Sea (INMUN1), and Sahar Air Cargo (INBOM4). In Yemen, major import ports are Hodeidah and Aden. These ports handle a significant volume of pharmaceutical imports, facilitating trade between the two countries.
Temperature-controlled logistics are essential for maintaining the efficacy of pharmaceutical products during transit. Good Distribution Practice (GDP) compliance ensures that products are stored and transported under appropriate conditions. Packaging standards must adhere to international guidelines to prevent contamination and ensure product integrity.
EXPORT_OPPORTUNITY
Market size, healthcare system, growth outlook
Yemen's pharmaceutical market is substantial, with imports valued at $127.85 million in 2019. The market is characterized by a high dependency on imports, with generics comprising a significant portion of the market share. This presents a growing opportunity for Indian exporters to meet the increasing demand for affordable and quality medicines.
Yemen's government healthcare programs focus on providing essential medical services to the population. However, challenges such as limited infrastructure and resources affect the efficiency of drug procurement systems. The reliance on international aid and imports underscores the need for reliable pharmaceutical suppliers like India.
Indian exporters have opportunities to supply a wide range of pharmaceutical products to Yemen, particularly in therapeutic areas such as infectious diseases, chronic conditions, and maternal and child health. The growth outlook for Indian pharma in Yemen is positive, driven by the country's healthcare needs and the established trade relationship.
EXPORT_COMPETITIVE
Competing origins, India's edge, challenges and threats
Other countries supplying pharmaceuticals to Yemen include China, the European Union, and regional neighbors like Saudi Arabia and the United Arab Emirates. In 2022, China exported $526.86K worth of hygienic or pharmaceutical articles of vulcanized rubber to Yemen. While these competitors have a presence in the Yemeni market, India's established trade relationship and product diversity provide a competitive edge.
India's advantages in the Yemeni pharmaceutical market include cost-effective production, adherence to WHO-GMP standards, and a broad portfolio of products. These factors enable Indian exporters to offer high-quality medicines at competitive prices, meeting the diverse needs of the Yemeni population.
Key challenges include potential regulatory tightening in Yemen, competition from other suppliers, and perceptions of quality. The geopolitical situation in the region can also impact trade routes and logistics. Indian exporters should proactively address these challenges to maintain and
India exported pharmaceuticals worth $34.5M to Yemen across 2,863 verified shipments.
1. CIPLA LIMITED — $4.0M. 2. MEDICEF PHARMA — $2.2M. 3. SCOTT EDIL PHARMACIA LIMITED — $1.8M. Total: 145 suppliers.
1. MEDICA PHARMACEUTICAL INDUSTRIES L — $2.2M. 2. AL JABAL DRUGS & MEDICAL APPLIANCE — $1.8M. 3. UNFPA YEMEN — $1.7M. 142 buyers total.
1. Other Mix Vaccine-liquid Vaccine ($1.4M, 4.0%); 2. Zinnia F 3x28 S Yemen Moh Packs 530208 ($1.3M, 3.9%); 3. Solpafizz (paracetamol 500 MG + Caffeine 65 MG Effervescent Tablets) ($461.1K, 1.3%); 4. Ph.dru.& Med.: Human Albumin EP 20% Solution (albucel (ep) 10g/50ml) [1x50ml] ($380.6K, 1.1%); 5. Erythromycin Stearate Tablets BP 250mg (47388 X 10 X 10 ) -box ($317.5K, 0.9%)
Export: NHAVA SHEVA SEA (INNSA1), MUNDRA SEA (INMUN1), SAHAR AIR CARGO ACC (INBOM4), SERUM BIOPHARMA PARK SEZ, KAMARAJAR PORT (INENR1). Import: Hodeidah, Aden, Salalah, Sana'a, SANAA.
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $34.5M corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$12.0K per consignment across 2,863 shipments.
145 Indian companies. Largest: CIPLA LIMITED with $4.0M.
TransData Nexus covers 145 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 2,863 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
145 Exporters
142 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists